Liposome nano‐formulation with cationic polar lipid DOTAP and cholesterol as a suitable pH‐responsive carrier for molecular therapeutic drug (all‐ trans retinoic acid) delivery to lung cancer cells

Abstract

The molecular targeted drug ATRA demands a suitable carrier that delivers to the cancer site due to its poor bioavailability and drug resistance. ATRA, being a lipid with carboxylic acid, has been nano-formulated as a cationic lipo-ATRA with DOTAP:cholesterol:ATRA (5:4:1) and its pH-responsive release, intracellular drug accumulation, and anticancer effect on human lung cancer (A549) cell line analysed. The analysis of the physicochemical characteristics of the developed lipo-ATRA (0.8 µmol) revealed that the size of 231 ± 2.35 d.nm had a zeta potential of 6.4 ± 1.19 and an encapsulation efficiency of 93.7 ± 3.6%. The ATRA release from lipo-ATRA in vitro was significantly (p ≤ 0.05) higher at acidic pH 6 compared to pH 7.5. The intracellular uptake of ATRA into lipo-ATRA-treated A549 cells was seven-fold higher (0.007 ± 0.001 mg/ml) while only threefold uptake was observed in free ATRA treatment (0.003 ± 0.002 mg/ml). The lipo-ATRA treatment caused a highly significant (p ≤ 0.001) decrease in percent cell viability at 48 h when compared with the free ATRA treatment. Overall, the results proved that the developed lipo-ATRA has suitable physicochemical properties with enhanced ATRA release at acidic pH, while maintaining stability at physiologic pH and temperature. This resulted in an increased ATRA uptake by lung cancer cells with enhanced treatment efficiency. Hence, it is concluded that DOTAP lipo-ATRA is a suitable carrier for ATRA delivery to solid cancer cells.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for rheumatoid arthritis therapy

“…In addition, both DS-RLs/DEX and DS-FLs/DEX displayed significant pH-dependent drug release properties. The possible reason for this phenomenon is that DOTAP, the main material of liposomes, has better solubility under acidic conditions, which makes the two liposomes exhibit acid-sensitive drug release characteristics (Grace et al., 2021 ). The cumulative low drug release at physiological pH helps to reduce the systemic toxic side effects of DEX.…”

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies

“…In patients with APL, tumor-activated group 2 innate lymphoid cells (ILC2s) secrete IL-13 to induce M-MDSCs (CD33 + CD14 + HLA-DR − ) and support tumor growth, while ATRA treatment reverses the increase in ILC2-MDSCs in APL [ 137 ]. Recently, lipid nanoformulations have been used as carriers of ATRA, improving the bioavailability of ATRA and the tumor treatment efficiency [ 138 ]. A selective inhibitor of JAK2/STAT3 signaling, cucurbitacin B (CuB), promotes the differentiation of MDSCs into DCs [ 139 ].…”

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

“…Furthermore, it exhibited increased release at acidic pH environments compared to neutral pH, which increases the absorption of ATRA by lung cancer cells, hence improving its therapeutic efficacy against them compared to the free drug. [ 111 ]…”

“…Furthermore, it exhibited increased release at acidic pH environments compared to neutral pH, which increases the absorption of ATRA by lung cancer cells, hence improving its therapeutic efficacy against them compared to the free drug. [111] Over many years of study, scientists have learned a great deal about the unique properties of cancer cells, giving them the ability to devise creative strategies for exploiting those properties in the form of nanocarriers. For example, it has been shown that tumor micro-environments have a lower pH than normal cells.…”